Here’s Who Oncotarget Is and Some Interesting Statistics About Them
Oncotarget is a medical journal – hence the root Onco in its name – created in 2010 by the top-tier pair of scientific researchers Mikhail Blagosklonny and Andrei V. Gudkov, both known well for their respective studies into intricacies, nuances, and new discoveries in the field of oncology. Founded in 2010, Oncotarget publishes new sets of peer-reviewed, scholarly journal articles regarding cancer, and is currently printed, edited, and published across various media by Impact Journals.
According to SCImago Journal and Country Rank, a database and evaluator of scientific journals and metrics that reveal information about countries’ – truly a leader in its field of accurate, complete compilations of scientific work – Oncotarget is ranked within the top 85 percent of scholarly, peer-reviewed journals regarding the practice, research, and study of cancer’s manifestation of humans and other animals and more information click here.
Unlike the majority – the vast majority – of scientific journals, Oncotarget is actually free to browse through and share with others, as its classification as an open sourced publication means everybody that has access to it, including everybody in the field of science who publishes research, college students studying related fields, and general purpose physicians and oncologists alike are not forced to pay or obtain copies illegally in order to simply read them and expand their bases of knowledge.
And even though Oncotarget doesn’t charge a single penny to use, it publishes multiple publications each and every week. Fortunately for everybody involved in the research and treatment of cancer, Oncotarget recently started releasing two – count ’em, two – issues a week, which are published each and every Friday and Tuesday and learn more about Oncotarget.
Oncotarget is unarguably a highly reputable publication, so much that its two weekly versions are included in PubMed, one of the most easily recognized sites that host one-time, irregular, and scheduled article and journal releases and its Facebook.
Because Oncotarget is free for everyone to read, cite, and otherwise use, it’s had more references in the past calendar year than any of the other 344 publications related to cancer, ranking in at right under 300,000 at 299,768. Oncotarget is undoubtedly one of the best publications related to the evils of cancer in our modern world.